clinical trials – mycolab.ai

If psychedelics heal, how do they do it?

mycolabadmin

Psychedelic drugs like MDMA and magic mushrooms are showing remarkable promise in treating serious mental health conditions like PTSD and depression, with clinical trials demonstrating higher success rates than traditional therapy alone. However, scientists still don’t fully understand how these drugs work at the molecular and brain level, or whether the hallucinations they produce are necessary for healing. Researchers are investigating whether modified versions without hallucinations could provide the same benefits while being easier to administer, while also exploring how individual factors and treatment environment affect outcomes.

Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials

mycolabadmin

This comprehensive review examines how medicinal mushrooms contain natural compounds that can boost immune function, fight cancer cells, reduce inflammation, and protect nerve cells. Different mushroom species like reishi, shiitake, and maitake contain various active substances such as beta-glucans and triterpenes that work through multiple biological pathways. While laboratory and animal studies show promising results, more human clinical trials are needed to confirm effectiveness and establish safe dosing guidelines.

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US

mycolabadmin

Researchers are studying psilocybin, a compound from certain mushrooms, as a potential treatment for depression, anxiety, and addiction. The United States has significantly more clinical trials underway than the European Union, reflecting different regulatory approaches and funding levels. While US trials progress faster, EU trials emphasize safety and careful evaluation. Both regions show promising results when psilocybin is combined with professional psychological support in controlled settings.

Clinically proven natural products against breast cancer, with mechanistic insights

mycolabadmin

This comprehensive review examines ten natural products that have been proven in clinical studies to help fight breast cancer. These products—including omega-3 fatty acids from fish, compounds in broccoli sprouts, garlic, soy, curcumin from turmeric, and green tea—work by triggering cancer cells to self-destruct, stopping their growth, and preventing blood vessel formation that feeds tumors. What makes these findings especially promising is that these natural products appear to work well alongside conventional treatments while causing minimal side effects, offering patients additional options for managing this serious disease.

Psilocybin for clinical indications: A scoping review

mycolabadmin

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Driving Innovation Through Regulatory Design and Corporate Behaviour: A Case Study of Functional Food Industry in Japan

mycolabadmin

This study examines how government regulations on health claims for dietary supplements affect how companies in Japan develop and sell these products. The research found that companies willing to invest in their own clinical trials to prove their products work tend to create more successful products and gain bigger market share. The study suggests that well-designed regulations can actually encourage companies to invest more in research and create better, more innovative products rather than just copying existing ones.

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

mycolabadmin

This study compared psychedelic drugs (psilocybin, LSD, MDMA, ayahuasca) with the antidepressant escitalopram for treating depression. Researchers analyzed 19 clinical trials and found that while psilocybin showed promise, its actual effectiveness was smaller than previously reported due to blinding issues in earlier studies. High-dose psilocybin performed better than escitalopram in some comparisons, but had a similar small effect size to current antidepressants.

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

mycolabadmin

This review examines how psychedelic substances like psilocybin and MDMA, when combined with professional psychotherapy, show promise in treating difficult-to-treat mental health conditions including depression, PTSD, and anxiety. While early research suggests these substances could help in cases where conventional treatments have failed, the evidence is still preliminary and limited by small study sizes. Psychedelics appear to work by changing how the brain processes information and memories, though much more rigorous research is needed before they can be considered standard treatments.

Psychedelics and Suicide-Related Outcomes: A Systematic Review

mycolabadmin

This comprehensive review examined how psychedelic substances like psilocybin and MDMA affect suicidal thoughts. Overall, psilocybin and MDMA-assisted therapy showed promise in reducing suicidal ideation in controlled clinical settings, with effects appearing within weeks. However, LSD use was associated with increased suicidal thoughts. The researchers conclude that while psychedelics show potential, more research is needed to ensure safety and understand how they work.

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework

mycolabadmin

Psychedelic drugs like LSD and psilocybin show promise in treating depression with effects lasting months after single doses. However, scientists debate whether the hallucinations and mystical experiences these drugs produce are necessary for their healing effects. This review proposes a framework to test whether lower doses without hallucinations might still provide antidepressant benefits, similar to how anesthesia-administered ketamine works without the patient’s awareness.

Research Topic: clinical trials